Rationale: Adults hospitalized for community-acquired pneumonia (CAP) have an increased risk of myocardial infarction. Corticosteroid treatment lowers CAP morbidity and mortality, but it is not known whether it influences in-hospital myocardial infarction. Objectives: The aim of the present study was to investigate the potential interplay between corticosteroid treatment and in-hospital myocardial infarction in adults with CAP. Methods: We retrospectively analyzed adults with CAP referred to the University Hospital Policlinico Umberto I (Rome, Italy), consecutively recruited, and prospectively followed until discharge. The primary outcome was the occurrence of myocardial infarction during hospitalization. We used propensity score–adjusted Cox models to examine the association between corticosteroid use and myocardial infarction. Results: Seven hundred fifty-eight patients (493 males, 265 females; mean 6 standard deviation age, 71.7 6 14.4 yr) were included in the study. Of these, 241 (32%) were treated with systemic corticosteroids (methylprednisolone, betamethasone, or prednisone). During followup, 62 (8.2%) had a myocardial infarction during their hospitalization (incidence, 0.72 per 100 person-days; 95% confidence interval [CI], 0.55 to 0.92). Those treated with corticosteroids had a lower incidence of myocardial infarction (0.42 per 100 person-days) than those not treated with corticosteroids (0.89 per 100 person-days; absolute rate difference, 20.48 per 100 person-days; 95% CI, 20.85 to 20.10). In a propensity score–adjusted Cox model, corticosteroid use was associated with a lower incidence of myocardial infarction (hazard ratio, 0.46; 95% CI, 0.24 to 0.88; P = 0.02). Conclusions: We found that in-hospital corticosteroid treatment was associated with a lower incidence of myocardial infarction in adults hospitalized with CAP.

Corticosteroid use and incident myocardial infarction in adults hospitalized for community-acquired pneumonia

Raparelli, Valeria
Membro del Collaboration Group
;
2019

Abstract

Rationale: Adults hospitalized for community-acquired pneumonia (CAP) have an increased risk of myocardial infarction. Corticosteroid treatment lowers CAP morbidity and mortality, but it is not known whether it influences in-hospital myocardial infarction. Objectives: The aim of the present study was to investigate the potential interplay between corticosteroid treatment and in-hospital myocardial infarction in adults with CAP. Methods: We retrospectively analyzed adults with CAP referred to the University Hospital Policlinico Umberto I (Rome, Italy), consecutively recruited, and prospectively followed until discharge. The primary outcome was the occurrence of myocardial infarction during hospitalization. We used propensity score–adjusted Cox models to examine the association between corticosteroid use and myocardial infarction. Results: Seven hundred fifty-eight patients (493 males, 265 females; mean 6 standard deviation age, 71.7 6 14.4 yr) were included in the study. Of these, 241 (32%) were treated with systemic corticosteroids (methylprednisolone, betamethasone, or prednisone). During followup, 62 (8.2%) had a myocardial infarction during their hospitalization (incidence, 0.72 per 100 person-days; 95% confidence interval [CI], 0.55 to 0.92). Those treated with corticosteroids had a lower incidence of myocardial infarction (0.42 per 100 person-days) than those not treated with corticosteroids (0.89 per 100 person-days; absolute rate difference, 20.48 per 100 person-days; 95% CI, 20.85 to 20.10). In a propensity score–adjusted Cox model, corticosteroid use was associated with a lower incidence of myocardial infarction (hazard ratio, 0.46; 95% CI, 0.24 to 0.88; P = 0.02). Conclusions: We found that in-hospital corticosteroid treatment was associated with a lower incidence of myocardial infarction in adults hospitalized with CAP.
2019
Cangemi, Roberto; Falcone, Marco; Taliani, Gloria; Calvieri, Camilla; Tiseo, Giusy; Romiti, Giulio Francesco; Bertazzoni, Giuliano; Farcomeni, Alessio; Violi, Francesco; Battaglia, Simona; Biliotti, Elisa; Calabrese, Cinzia Myriam; Celestini, Andrea; Casciaro, Marco; De Angelis, Maurizio; Di Diego, Ilaria; De Marzio, Paolo; Esvan, Rozenn; Ferraro, Giovanni; Sulekova, Lucia Fontanelli; Franchi, Cristiana; Giordo, Laura; Khoury, Fuad; Morelli, Sergio; Catassi, Giulia Naspi; Palange, Paolo; Pastori, Daniele; Prosperi, Anna; Raparelli, Valeria; Capparuccia, Marco Rivano; Rossi, Elisabetta; Scarpellini, Maria Gabriella; Trapè, Stefano; Toriello, Filippo; Vano, Marco; Venditti, Mario
File in questo prodotto:
File Dimensione Formato  
Cangemi_Corticosteroid_2019.pdf

solo gestori archivio

Descrizione: versione editoriale
Tipologia: Full text (versione editoriale)
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 578.89 kB
Formato Adobe PDF
578.89 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2433872
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 30
social impact